Catalent Biologics News and Activities

Catalent Biologics is owned by Catalent Pharma Solutions.

Catalent Pharma Solutions is one of the...

• Fortune 500 (#711);
• TOB Iconic 10,000.

Catalent Pharma Solutions is a company listed under the stock ticker CTLT (US).

Catalent Pharma Solutions has a direct presence in 2 countries.

Catalent Pharma Solutions has 3 subsidiaries including Catalent Biologics, Catalent Cell & Gene Therapy and Catalent Pharma Germany.

They are in:

• Pharmaceuticals50%
• Biotechnology50%

View the org chart displaying its 3 main executives

Most searched biographies at Catalent Biologics

• David Mcerlane, Group President
• Jean-Francois Boe, Director, Drug Product Development
• Ricardo Zayas, Senior Vice President, Global Operations

Create your alert
to follow the executive moves at Catalent Biologics.

Catalent Pharma Solutions has 2,405 competitors including Eurofins (Luxembourg), Lonza (Switzerland) and BioNTech (Germany).

Popular M&A news in Biotechnology

• Ona Therapeutics has just announced a $87 Million fundraising (posted on June 5 2026).
• Laboratoire Servier has announced the acquisition of Edgewise Therapeutics  (posted on June 4 2026).
• Oak Hill Bio has just announced a $33 Million fundraising (posted on June 4 2026).

Popular contacts in Biotechnology

• Jakob Uszkoreit - Co-Founder and Chief Executive Officer at Inceptive
• Jan Van de Winkel - President and Chief Executive Officer at Genmab
• Patrick Enright - Director at CuraSen Therapeutics

Learn more about the Biotechnology industry

Press releases by Catalent Biologics

• Silexion Therapeutics Announces Collaboration with Global Therapeutics Leader Catalent on Advanced siRNA Formulation Development & Clinical Manufacturing Activities
• Catalent Announces Collaboration with Galapagos to Further Expand Galapagos’ Decentralized CAR-T Manufacturing Network in the U.S.
• IsomAb Announces Strategic Collaboration with Catalent
• Webinar: GPEx® Lightning: Achieving Rapid, High-Titer Expression for Next-Generation Biologics
• Siren Biotechnology and Catalent Enter Partnership for Manufacturing of AAV Gene Therapies for Cancer
• Catalent and JLABS Symposium to Discuss Accelerated Development and Manufacturing of Biologics
• Catalent Expands OneBio® Suite for Integrated Development, Manufacturing and Supply Across Biologic Modalities
• Catalent to Present on Integrated UpTempo℠ Gene Therapy Development Platform
• Catalent & Bhami Research Laboratory Enter into Licensing Agreement
• Catalent Expands UpTempo℠ AAV Platform to Accelerate Development of Gene Therapies
• View more press releases Close

Social media about Catalent Biologics

• Catalent Biologics on Wikipedia, Google News & Yahoo Finance
• Catalent Biologics on LinkedIn, X (Twitter) & YouTube